Добірка наукової літератури з теми "Hepatitis B Victoria Prevention"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Hepatitis B Victoria Prevention".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Hepatitis B Victoria Prevention"
Thompson, Sandra C., and Maureen Norris. "Hepatitis B Vaccination of Personnel Employed in Victorian Hospitals: Are Those at Risk Adequately Protected?" Infection Control & Hospital Epidemiology 20, no. 01 (January 1999): 51–54. http://dx.doi.org/10.1086/501552.
Повний текст джерелаFAYYAZ, MOHAMMAD, Muhammad Ayub Khan, MASROOR ALI QAZI, Ghulam Mohyud Din `Chaudhary, and GULZAR AHMED. "HEPATITIS B, C & HIV." Professional Medical Journal 13, no. 04 (December 16, 2006): 632–36. http://dx.doi.org/10.29309/tpmj/2006.13.04.4941.
Повний текст джерелаAdamson, E., N. Yussf, and E. Schreiber. "Using Liver Cancer Prevention Messages to Scale up the Diagnosis and Treatment of People Living With Hepatitis B." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 132s. http://dx.doi.org/10.1200/jgo.18.32800.
Повний текст джерелаMacLachlan, Jennifer H., and Benjamin C. Cowie. "Uptake and trends in ordering of funded hepatitis B immunisation for priority populations in Victoria, Australia, 2013–2014." Sexual Health 14, no. 2 (2017): 188. http://dx.doi.org/10.1071/sh16002.
Повний текст джерелаBody, Amy, Jennifer F. Hoy, Allen C. Cheng, and Michelle L. Giles. "Incident hepatitis B infection subsequent to the diagnosis of HIV infection in a Melbourne cohort: missed opportunities for prevention." Sexual Health 11, no. 1 (2014): 5. http://dx.doi.org/10.1071/sh13019.
Повний текст джерелаDAUD, SEEMA, IRAM MANZOOR, and NOREEN RAHAT HASHMI. "PREVENTION OF HEPATITIS B." Professional Medical Journal 14, no. 04 (October 12, 2007): 634–38. http://dx.doi.org/10.29309/tpmj/2007.14.04.4829.
Повний текст джерелаChang, M. H., and D. S. Chen. "Prevention of Hepatitis B." Cold Spring Harbor Perspectives in Medicine 5, no. 3 (March 1, 2015): a021493. http://dx.doi.org/10.1101/cshperspect.a021493.
Повний текст джерелаBastien, M. R. "Prevention of hepatitis B." Archives of Dermatology 125, no. 2 (February 1, 1989): 212–15. http://dx.doi.org/10.1001/archderm.125.2.212.
Повний текст джерелаBastien, Michael R. "Prevention of Hepatitis B." Archives of Dermatology 125, no. 2 (February 1, 1989): 212. http://dx.doi.org/10.1001/archderm.1989.01670140064010.
Повний текст джерелаPoland, Gregory A., and Robert M. Jacobson. "Prevention of Hepatitis B with the Hepatitis B Vaccine." New England Journal of Medicine 351, no. 27 (December 30, 2004): 2832–38. http://dx.doi.org/10.1056/nejmcp041507.
Повний текст джерелаДисертації з теми "Hepatitis B Victoria Prevention"
Sangfelt, Per. "Prevention and treatment of hepatitis B virus infection /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-301-9/.
Повний текст джерелаReed, Barry Edwin. "The implications of hepatitis B for dental practice." University of Sydney, 1987. http://hdl.handle.net/2123/4834.
Повний текст джерелаThis work was digitised and made available on open access by the University of Sydney, Faculty of Dentistry and Sydney eScholarship . It may only be used for the purposes of research and study. Where possible, the Faculty will try to notify the author of this work. If you have any inquiries or issues regarding this work being made available please contact the Sydney eScholarship Repository Coordinator - ses@library.usyd.edu.au
Zuckerman, Jane Nicola. "Prevention of viral hepatitis A and B by immunisation." Thesis, University College London (University of London), 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.336638.
Повний текст джерелаMachiya, Tichaona. "Knowledge, attitudes and practices of healthcare workers at the Princess Marina Hospital in Botswana, regarding hepatitis B prevention and control." Thesis, University of Limpopo (Medunsa Campus), 2011. http://hdl.handle.net/10386/457.
Повний текст джерелаIntroduction: Hepatitis B virus (HBV) is a highly infectious virus responsible for considerable morbidity and mortality world wide. Chronic HBV carriers can transmit HBV parenterally in a hospital setting putting healthcare workers (HCWs) and their patients at risk of infection. Aim and objectives: This study aimed to investigate knowledge, attitudes and practices towards prevention and control of HBV amongst nurses, doctors and laboratory personnel. Objectives were to determine: (a) the knowledge; (b) the attitudes; (c) the practices of nurses, doctors and laboratory personnel; (d) if there are any associations between (1) knowledge and practice, and (2) attitudes and practice; (e) the predictors of HBV vaccination uptake. Materials and Methods: This was a cross-sectional descriptive study. Self-administered questionnaires were distributed to doctors, laboratory staff and nurses at Princess Marina Hospital. Results: Two hundred questionnaires were distributed and a total of 117 were returned, giving an overall response rate of 58.5%. More doctors had good knowledge (38.9% [7/18]), followed by 20% (4/20) of laboratory staff and 11.4% (9/79) of nurses. Most staff (100% [20/20] of laboratory staff; 97.5% [77/79] of nurses; 94.4% [17/18] of doctors) had positive attitudes. More laboratory staff (100 [20/20]) displayed good practices, followed by nurses (94.9% [75/79]); and lastly doctors (88.9% [16/18]). There were no significant associations between knowledge or attitudes and practices. Vaccination was inadequate, with 50.9% (59/116) of HCWs having received at least one dose, and of these only 61% (36/59) receiving all 3 doses. Needle stick injuries occurred in 31.6% (37/117), while 33.9% (39/115) reported blood or body fluid splashes. None of the HCWs accessed PEP after exposure. Being a laboratory worker (OR: 148.4) or doctor (OR: 125.7) were the only predictors of vaccination uptake. Conclusion: There is need to increase knowledge of HCWs, vaccination availability, vaccination uptake, PEP, and reduce the exposures of HCWs.
Ohlson, Emilia, and Frida Bladh. "Knowledge about hepatitis B and attitudes towards hepatitis B vaccination among university students in Thailand : A quantitative study." Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-272494.
Повний текст джерелаYuen, Man-fung, and 袁孟峰. "Chronic hepatitis B virus infection in the Chinese: natural history, sequelae, treatment and prevention." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2000. http://hub.hku.hk/bib/B2333177X.
Повний текст джерелаSatekge, Mpho Margaret. "Knowledge, attitudes and practices regarding the prevention of hepatitis B virus infections, in final year college student nurses in Gauteng Province." Thesis, University of Limpopo (Medunsa Campus), 2010. http://hdl.handle.net/10386/236.
Повний текст джерелаIntroduction: Hepatitis B infection is a serious blood-borne disease caused by the hepatitis B virus (HBV) which attacks the liver, and is the leading cause of liver cancer and cirrhosis of the liver. HBV can be transmitted through exposure to infected blood and human secretions through needle stick / sharps injuries and splashes. Thus nurses are at high risk for HBV infection. The aim of the study: To investigate the knowledge, attitudes and practices (KAP) regarding the prevention of hepatitis B virus infections, in final year college student nurses in Gauteng province. Methods: A cross-sectional quantitative survey on 350 final year nursing students was conducted in three Gauteng province nursing colleges, using an anonymous self administered questionnaire with questions on knowledge, attitudes, and practices regarding HBV. The data were analysed using SPSS (statistical package for social science studies). Results: Of 350 questionnaires distributed, 312 student nurses returned completed forms (response rate: 89.14% [312/350]). The majority were females (86.8% [270/331]) and were below 31 years of age (30.1% [93/309]). The majority (87.6% [271/310]) had good knowledge of the causes and prevention of HBV. The unvaccinated respondents had fairly low positive attitudes, with a mean, mode and median score of 1 (possible score from -4 to +4). The majority (79% [244/310]) practiced good compliance with universal precautions of, and the majority (64.9% [202/311]) were vaccinated. College A displayed significantly higher knowledge (p<0.001), positive attitudes (p=0.001) and safer practices (p<0.001) than college B and C.
Lukhwareni, Azwidowi. "Exploring the Impact of Human Immunodeficiency Virus on Hepatitis B Virus Diagnosis, Prevention and Control in Co-infected Adult South African Patients on Highly Active Antiretroviral Therapy." Thesis, University of Limpopo (Medunsa), 2008. http://hdl.handle.net/10386/242.
Повний текст джерелаBackground and Objectives: South Africa is one of the countries highly affected by human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. Some drugs (e.g. lamivudine) used as part of combination antiretroviral regimens for HIV treatment have dual activity against HBV and HIV. Despite high infection rate with both viruses, routine screening for HBV before initiation of treatment for HIV is not yet a standard practice. This study undertook to investigate: (1) the burden of HBV co-infection in HIV-positive patients enrolling for highly active antiretroviral therapy (HAART) at Dr George Mukhari hospital, (2) the impact of anti-HBV containing HAART regimens on HBV during the management of HBV/HIV co-infected patients, (3) the co-evolution of HBV and HIV drug-resistant strains, and (4) the correlation of HBV genotypes with response to anti-HBV containing HAART regimens. Study Population and Methods: To investigate the burden of HBV/HIV co-infections, a cohort of 192 HIV patients who were candidates for ARV treatment at Dr George Mukhari hospital were studied by screening for HBV serological markers (HBsAg, anti-HBs and anti- HBc) (Elecsys 2010, Roche Diagnostics) and HBV DNA with an in-house nested PCR assay targeting HBV polymerase gene. Quantitation of HBV DNA positive samples was performed with Roche Cobas Taqman HBV test 48 assay. To investigate the impact of lamivudine-containing HAART regimens on HBV during the management of HBV/HIV co-infected patients, as well as the coevolution of HBV and HIV drug-resistant strains, a total of 78 patients were studied. HBV virological response against lamivudine containing-HAART regimens [1a (lamivudine, stavudine and efaverenz); 1b (lamivudine, stavudine and neviripine)] was measured (Cobas Taqman HBV test 48, Roche diagnostics). HBV direct sequencing targeting HBV polymerase gene was performed on all baseline samples (n=78) and additional samples collected at various time points (n = 45). Direct sequencing was also performed on 30 HIV baseline samples targeting the HIV reverse transcriptase and protease genes (Spectru-Medix SCE 2410 Genetic Analysis System and ABI PRISM® 3100 Genetic Analyzer version 3.7). To explore the genetic diversity of HBV and HIV strains circulating in Pretoria and surrounding areas, as well as the correlation of HBV genotypes with response to lamivudine-containing-HAART regimens in co-infected patients, all baseline and follow-up HBV and HIV sequences were analysed, compared and correlated with treatment. Sequence alignments and phylogenetic studies for both HBV and vi HIV were conducted with MAFFT, Mega 4 and neighbour joining phylogenetic trees generated with the PHYLIP programme. Results: Three significant findings were observed in this study. Firstly, the majority of South African HIV patients enrolling for HAART were exposed to HBV infection and either had acute or chronic HBV infections. A total of 63.0% of patients were found to have one or more HBV markers, with 40.6% having detectable HBV DNA as an indication of replication. The study also detected 22.9% with positive HBsAg, and 23% of 77% HBsAg-negative patients having occult hepatitis B infection. Secondly, HBV/HIV co-infected patients do benefit during the management of HIV infections with lamivudine-containing HAART regimens. A total of 68.4% of patients responded to HAART, with undetectable HBV DNA during 18 to 24 months of follow-up. A total of 91.3% of HIV patients also responded to HAART with an undetectable HIV viral load during 6 to 12 months of follow-up. However, a total of 18% of patients had persistent HBV DNA, yielding various HBV virological responses against lamivudine containing-HAART regimens. This proportion of patients poses a question regarding the management of HBV and HIV coinfections, as guidelines on the use of HAART with anti-HBV activity from developed countries, may not necessarily be followed in developing countries. The results further showed that baseline drug-resistance was more frequent with HIV than HBV in this cohort of patients. The following HIV primary drug resistant mutants were observed: nine major NRT's primary mutants, M41L (1/30), E44A (1/30), V75M (1/30), F77L (1/30), V118I (1/30), M184V (1/30), L210S (1/30), T215Y (1/30) and V90I (1/30), and five major NNRT’s primary mutants were also detected, K103N (3/30), Y318CFSY (1/30), E138Q (1/30), P225H (1/30) and K238T. However, all followup samples had undetectable HIV viral load. In contrast to HIV, only one patient was detected with HBV mutant, M204I, at baseline. The mutant reversed to wild type during 6 months and other follow-up (12, 18 and 24 months). Finally, this study indicated that the HBV genotype A is still the most prevalent genotype circulating in South Africa. Of the 78 HBV sequences, 77 were genotype A and 1 sequence was genotype G. This is the first report from Africa of the detection of HBV genotype G. HIV subtype C remains the predominant prevailing subtype in South Africa. HBV genotype or HIV subtype C was not observed to influence any treatment outcome following treatment with vii lamivudine-containing HAART regimens. The study also indicated that patients on lamivudinecontaining HAART regimens do benefit not only by suppressing HIV and HBV viral load, but also improving immunity (i.e. CD4 cells count increases). Conclusion: Overall, the present study highlights the need for screening HBV before initiation of any HAART containing anti-HBV regimens in HBV/HIV co-infected patients. It necessitates the use of molecular assays for effective laboratory in diagnosis of occult HBV infections in HIVpositive patients, especially in developing countries where these assays are not widely available. While lamivudine-containing HAART regimens do benefit both HBV and HIV patients in co-infected individuals, however, whether HBV virological response is temporary or sustained is unknown at this stage. What is certain is that these patients require an effective monitoring programme as (1) a small percentage experience variable HBV virological responses (partial, reactivation, or no response), and (2) hepatitic flares are likely to develop if HAART is terminated (e.g. by patient), or the current HAART regimen is switched to another regimen without anti-HBV activity. HBV genotype A remains the dominant genotype in South Africa, but novel genotypes can be detected. HIV subtype C was found to be the prevalent subtype. HBV genotype or HIV subtype C were not seen to influence any treatment outcome following treatment with lamivudine-containing HAART regimens. Recommendations: HIV patients should be screened for HBV before initiation of anti-HBV containing HAART regimens. The screening of HBV in HIV patients is also important since some drugs included as part of HAART (e.g. nevirapine) may cause hepatotoxicity and exacerbate HBV infections leading to increased morbidity and mortality due to liver complications. Immunization and immune boosters of HIV patients with low (< 10IU/L) or no immunity against HBV should be done as this could be beneficial, although these patients may not respond optimally, or their immunity may wane faster due to immunocompromised status. Monitoring of both HBV and HIV resistant strains should be conducted for timely detection for the occurrence of multiple resistant mutations, which could limit future therapeutic option for both viruses.
Mancke, Lida Victoria [Verfasser], and Maura [Akademischer Betreuer] Dandri. "Humanized chimeric uPA mouse model for the study of Hepatitis B and D virus interactions and preclinical drug evaluation / Lida Victoria Mancke. Betreuer: Maura Dandri." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2013. http://d-nb.info/1032990562/34.
Повний текст джерелаШуль, У. А., та О. В. Чудінова. "Епідеміологічні особливості вірусного гепатиту В у м. Львові за 2012-2014 роки". Thesis, Сумський державний університет, 2015. http://essuir.sumdu.edu.ua/handle/123456789/43165.
Повний текст джерелаКниги з теми "Hepatitis B Victoria Prevention"
Centers for Disease Control (U.S.), ed. Hepatitis B prevention and pregnancy: How to protect your baby against hepatitis B. Atlanta, Ga: Hepatitis Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control, 1994.
Знайти повний текст джерела1968-, Zhang Weiying, and Ye Lihong, eds. Hepatitis B virus research focus. New York: Nova Science Publishers, 2008.
Знайти повний текст джерелаBelec, Michel. Programme de lutte contre l'hépatite B. [Mamoudzou]: Collectivité territoriale de Mayotte, Direction des affaires sanitaires et sociales, 1993.
Знайти повний текст джерелаNew York (State). Dept. of Health., ed. Perinatal hepatitis B prevention program: 1990-1993 report. [New York]: The Department, 1993.
Знайти повний текст джерелаYin, Guoyou. Yi xing gan yan fan zhi 30 fa. Beijing: Jin dun, 2002.
Знайти повний текст джерелаCanada. Parliament. House of Commons. Standing Committee on Health and Welfare, Social Affairs, Seniors and the Status of Women. Hepatitis B: Report of the Standing Committee on Health and Welfare, Social Affairs, Seniors and the Status of Women. [Ottawa]: Queen's Printer for Canada, 1992.
Знайти повний текст джерелаCanada, Parliament House of Commons Standing Committee on Health and Welfare Social Affairs Seniors and the Status of Women. Hepatitis B: Issue no. 6 of Minutes of proceedings and evidence of the Standing Committee on Health and Welfare, Social Affairs, Seniors and the Status of Women. [Ottawa]: Queen's Printer for Canada, 1992.
Знайти повний текст джерелаReform, United States Congress House Committee on Oversight and Government. Viral hepatitis: The secret epidemic : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Eleventh Congress, second session, June 17, 2010. Washington: U.S. G.P.O., 2011.
Знайти повний текст джерелаThe war against hepatitis B: A history of the International Task Force on Hepatitis B Immunization. Philadelphia: University of Pennsylvania Press, 1995.
Знайти повний текст джерелаSaskatchewan Subcommittee on HIV/AIDS. Guidelines for the management of potential exposures to Hepatitis B, Hepatitis C, HIV, and recommendations for post-exposure prophyalxis. Saskatchewan: Saskatchewan Health, 2004.
Знайти повний текст джерелаЧастини книг з теми "Hepatitis B Victoria Prevention"
Karaca, Nilay, and Çetin Karaca. "Prevention of Mother-to-Child Transmission of HBV." In Viral Hepatitis: Chronic Hepatitis B, 65–70. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93449-5_6.
Повний текст джерелаMichalak, Tomasz I. "Immunology of hepatitis B virus." In Hepatitis Prevention and Treatment, 87–105. Basel: Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7903-3_5.
Повний текст джерелаBlatt, Lawrence M., and Myron Tong. "Epidemiology of chronic hepatitis viruses: hepatitis B virus and hepatitis C virus." In Hepatitis Prevention and Treatment, 29–38. Basel: Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7903-3_2.
Повний текст джерелаPrince, Alfred M., Richard Mahoney, and James Maynard. "Prevention of Hepatitis B Infection." In Viral Hepatitis and Liver Disease, 517–19. Tokyo: Springer Japan, 1994. http://dx.doi.org/10.1007/978-4-431-68255-4_134.
Повний текст джерелаCondreay, Lynn D., and Sarah A. Harris. "Molecular virology of hepatitis B virus." In Hepatitis Prevention and Treatment, 39–65. Basel: Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7903-3_3.
Повний текст джерелаChang, Mei-Hwei. "Hepatitis B Virus and Cancer Prevention." In Clinical Cancer Prevention, 75–84. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-10858-7_6.
Повний текст джерелаKurstak, Edouard. "Control and prevention of hepatitis B virus infection." In Viral Hepatitis, 128–48. Vienna: Springer Vienna, 1993. http://dx.doi.org/10.1007/978-3-7091-4437-4_16.
Повний текст джерелаBrown, Nathaniel A., and Richard E. Boehme. "Current treatment of patients with chronic hepatitis B virus infection." In Hepatitis Prevention and Treatment, 125–40. Basel: Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7903-3_7.
Повний текст джерелаUmenai, Takusei, Takashi Takahashi, Yoji Goto, Toshio Akiba, and Nobuhiko Okabe. "Prevention of Hepatitis B in Asia." In Viral Hepatitis and Liver Disease, 520–21. Tokyo: Springer Japan, 1994. http://dx.doi.org/10.1007/978-4-431-68255-4_135.
Повний текст джерелаChang, Mei-Hwei. "Prevention of Viral Hepatitis B and Related Complications." In Viral Hepatitis in Children, 133–48. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-0050-9_9.
Повний текст джерелаТези доповідей конференцій з теми "Hepatitis B Victoria Prevention"
Huang, Jiaqi, Måns Magnusson, Anna Törner, Weimin Ye, and Ann-Sofi Duberg. "Abstract A07: Risk of pancreatic cancer among individuals with hepatitis C or hepatitis B virus infection: A nationwide study in Sweden." In Abstracts: Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; Oct 27-30, 2013; National Harbor, MD. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1940-6215.prev-13-a07.
Повний текст джерелаAlMunif, Sara, Nouf Al Enizi, and Majid AlShamrani. "72 Prevention of mother-to-child transmission of hepatitis B in king abdulaziz medical city, riyadh." In Patient Safety Forum 2019, Conference Proceedings, Kingdom of Saudi Arabia, Ministry of National Guard Health Affairs. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/bmjoq-2019-psf.72.
Повний текст джерелаMiralles Andreu, G., M. Pomares Bernabeu, S. Gutiérrez Palomo, IP Jiménez Pulido, L. Soriano Irigaray, and A. Navarro Ruiz. "5PSQ-156 Compliance of recommendations for the prevention of hepatitis B virus reactivation during daratumumab treatment." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.275.
Повний текст джерелаLow, Jia Ming, and Guan-Huei Lee. "289 Knowledge and awareness of maternal chronic hepatitis carriers to perinatal antiviral use in prevention of mother-to-child hepatitis B virus transmission." In RCPCH Conference Singapore. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/bmjpo-2021-rcpch.160.
Повний текст джерелаButarbutar, Tonggo Margareta, Misnaniarti, and Rostika Flora. "Correlation Between Timing of Hepatitis B Immunoglobulin to the Effectiveness of Mother to Child Transmission Prevention Program." In 2nd Sriwijaya International Conference of Public Health (SICPH 2019). Paris, France: Atlantis Press, 2020. http://dx.doi.org/10.2991/ahsr.k.200612.067.
Повний текст джерелаKumar, Vijay, Atish Mukherji, and Vaibhao Janbandhu. "Abstract B78: The X protein of hepatitis B virus induces PI3K/Akt pathway to overcome gentoxic stress-related cyclin D1 degradation and growth arrest." In Abstracts: Frontiers in Cancer Prevention Research 2008. American Association for Cancer Research, 2008. http://dx.doi.org/10.1158/1940-6207.prev-08-b78.
Повний текст джерелаCastro, Ana Rita Motta, Livia Lima, Larissa Bandeira, Selma Gomes, Barbara Lago, Grazielli Rezende, and Gabriela Alves Cesar. "Hepatitis B: changes in epidemiological features of Afrodescendant communities in Central Brazil." In XIII Congresso da Sociedade Brasileira de DST - IX Congresso Brasileiro de AIDS - IV Congresso Latino Americano de IST/HIV/AIDS. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/dst-2177-8264-202133p142.
Повний текст джерела"Knowledge, Attitude and Perception of Incomplete Hepatitis B Vaccination Among Staff of University College Hospital, Ibadan." In International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/rfob4613.
Повний текст джерелаFatimah, Mei, Supriyadi Hari Respati, and Eti Poncorini Pamungkasari. "Path Analysis Factors Affecting Pregnant Women Participation to The Triple Elimination Examination in Semarang, Central Java." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.03.105.
Повний текст джерелаЗвіти організацій з теми "Hepatitis B Victoria Prevention"
A curriculum guide for public-safety and emergency-response workers. Prevention of transmission of human immunodeficiency virus and hepatitis B virus. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, February 1989. http://dx.doi.org/10.26616/nioshpub89108.
Повний текст джерела